



# EG-ZERTIFIKAT

(Vollständiges Qualitätssicherungssystem)



Hiermit wird bescheinigt, dass das Unternehmen

## Vepro AG Germany

Max-Planck-Str. 1-3  
64319 Pfungstadt  
Deutschland

ein vollständiges Qualitätssicherungssystem für jede Phase von der Auslegung bis zur Endkontrolle der Produkte eingeführt hat und anwendet.

Durch ein Audit, dokumentiert in einem Bericht, durchgeführt von DQS Medizinprodukte GmbH, wurde der Nachweis erbracht, dass dieses Qualitätssicherungssystem die Forderungen gemäß

## Anhang II – ohne Abschnitt 4 der Richtlinie 93/42/EWG des Rates über Medizinprodukte

bezüglich folgender Medizinprodukte erfüllt:

Software für digitale Bildarchivierung, -verarbeitung, und -  
kommunikation im medizinischen Bereich (PACS) Klasse IIa  
EMR Manager V10

Der Hersteller unterliegt der Überwachung nach Anhang II, Abschnitt 5. Die CE-Kennzeichnung mit der Kennnummer der Benannten Stelle (0297) darf an den auf dem Zertifikat gelisteten Produkten angebracht werden. Für das Inverkehrbringen von Klasse III Produkten ist eine EG Produktauslegungsprüfung nach Anhang II, Abschnitt 4 notwendig. Das Zertifikat beschränkt sich für Produkte der Klasse I(s) (I(s) = Produkte der Klasse I die in sterilem Zustand in Verkehr gebracht werden) ausschließlich auf die Herstellung im Zusammenhang mit der Sterilisation und der Aufrechterhaltung der Sterilität. Das Zertifikat beschränkt sich für Produkte der Klasse I(m) (I(m) = Produkte der Klasse I mit Messfunktion) ausschließlich auf die Herstellung im Zusammenhang mit der Konformität der Produkte mit den messtechnischen Anforderungen.

Zertifikat-Registrier-Nr. 527544 MR2  
Zertifikat-ID 170743839  
Gültig ab 2019-10-08  
Gültig bis 2024-05-26  
Frankfurt am Main, den 2019-10-08

## DQS Medizinprodukte GmbH

Sigrid Uhlemann  
Geschäftsführerin

Dr. Thomas Feldmann  
Leiter der Zertifizierungsstelle

August-Schanz-Straße 21, 60433 Frankfurt am Main,  
Tel. +49 (0) 69 95427-300, [medical.devices@dqs-med.de](mailto:medical.devices@dqs-med.de)

Die DQS Medizinprodukte GmbH ist Benannte Stelle gemäß der Richtlinie 93/42/EWG des Rates über Medizinprodukte mit der Kennnummer 0297.



DQS Medizinprodukte GmbH | August-Schanz-Str. 21 | 60433 Frankfurt am Main

**Veuro AG Germany**

Max-Planck-Str. 1-3  
64519 Pfungstadt  
Germany

**2024-05-24**

**Notified Body Confirmation Letter**

**Reference: 170743839**

To whom it may concern,

**Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical device**

This letter confirms that, DQS Medizinprodukte GmbH, a Notified Body designated against Regulation (EU) 2017/745 (MDR) and identified by the number 0297 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

**Veuro AG Germany**

Max-Planck-Str. 1-3  
64319 Pfungstadt  
Germany  
SRN: DE-MF-000018755

The devices covered by the formal application and the written agreement mentioned above are identified in the Tables listed below: Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which DQS Medizinprodukte GmbH is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but DQS Medizinprodukte GmbH has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after 26 May 2021 and before 20 March 2023, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry, or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by the 20 Mar 2023 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- 26 May 2026 for Class III custom-made implantable devices
- 31 December 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- 31 December 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- 31 December 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body,



**Tim Unverzagt**

Regulatory Affairs Manager

**Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name and Basic UDI-DI (as proposed by the manufacturer within the application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
<b>EMR Manager V11</b>  <i>Basic UDI-DI:</i> 426075569EMRMANAGERCA	Class IIa	EMR Manager V10, class IIa	<i>MDD-Certificate References:</i> 527544 MR2 170743839  <i>NB Identification:</i> 0297 (DQS Medizinprodukte GmbH)

**Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

Device name and Basic UDI-DI (as proposed by the manufacturer within the application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
-	-	-	-

#### Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2024-05-24	170743839	Initial issue